LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_001127510.3:c.3205A>G
APC
· NP_001120982.1:p.(Arg1069Gly)
· NM_001127510.3
GRCh37: chr5:112174496 A>G
·
GRCh38: chr5:112838799 A>G
Gene:
APC
Transcript:
NM_001127510.3
Final call
Likely Benign
BS1 strong
BP1 supporting
Variant details
Gene
APC
Transcript
NM_001127510.3
Protein
NP_001120982.1:p.(Arg1069Gly)
gnomAD AF
1.4249780057742587e-05 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
Likely Benign: BS1 strong is met because gnomAD v2.1 Popmax AF 1.127e-05 exceeds the APC VCEP threshold of 0.00001.
2
Likely Benign: BP1 supporting is met because p.Arg1069Gly at codon 1069 lies outside the APC VCEP exception spanning codons 1021-1035.
Final determination:
APC InSiGHT VCEP Version 2.1 Rule26 is satisfied by one Benign.Strong criterion (BS1) together with the adjudicated benign evidence set including BP1 supporting, yielding Likely Benign.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.3205A>G is a missense substitution producing p.(Arg1069Gly), not a null variant covered by the APC PVS1 decision tree. |
cspec
vcep_fig_1_apc_pvs1_decision_tree_2023_10_20
|
| PS1 | Not met | Not met: no previously established pathogenic or likely pathogenic APC variant produces the same p.Arg1069Gly amino-acid change. |
cspec
PMID:34545850
|
| PS2 | Not assessed | Not assessed: two reported patients lack documented parental testing and a qualifying APC VCEP de novo score. |
cspec
PMID:34545850
|
| PS3 | Not assessed | Not assessed: no validated RNA or protein assay demonstrates increased beta-catenin transcription or decreased beta-catenin binding for APC p.Arg1069Gly. |
cspec
PMID:34545850
|
| PS4 | Not met | Not met: documented qualifying APC phenotype points are 0, below the VCEP's lowest PS4 band of 1-1.5 phenotype point. |
cspec
PMID:34545850
|
| PM1 | N/A | Not applicable: the APC VCEP explicitly designates PM1 as not applicable, and no APC domain-table interval is supplied. |
cspec
vcep_apc_specifications_supplementary_material_v2
|
| PM2 | Not met | Not met: gnomAD v4.1 AF 1.42498e-05 with AC 23 exceeds the APC VCEP PM2 threshold of 0.000003 for AC greater than one. |
cspec
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: the APC VCEP designates PM3 as not applicable for this autosomal-dominant disorder. |
cspec
|
| PM4 | N/A | Not applicable: p.(Arg1069Gly) is a missense substitution with no in-frame deletion, insertion, or protein-length change for PM4. |
cspec
vcep_apc_specifications_supplementary_material_v2
|
| PM5 | Not met | Not met: the residue-1069 search found 0 same-residue pathogenic or likely pathogenic comparator variants among 13 candidates. |
cspec
pm5_candidates
|
| PM6 | Not assessed | Not assessed: the two reported patients have no documented de novo status, parental testing, or phenotype-based APC score. |
cspec
PMID:34545850
|
| PP1 | Not assessed | Not assessed: no pedigree or informative meiosis count is reported for the two patients with the variant. |
cspec
PMID:34545850
|
| PP2 | N/A | Not applicable: the APC VCEP explicitly excludes PP2 because missense variants are not a frequent disease mechanism in APC. |
cspec
vcep_apc_specifications_supplementary_material_v2
|
| PP3 | Not met | Not met: missense REVEL 0.523 is below the PP3 Supporting threshold of 0.644 from the ClinGen SVI calibration. |
cspec
revel
|
| PP4 | N/A | Not applicable: the APC VCEP marks PP4 unavailable because phenotype specificity is handled through its PS4 phenotype-point system. |
cspec
|
| PP5 | N/A | Not applicable: the APC VCEP prohibits PP5, and no exact-variant ClinVar expert-panel Pathogenic or Likely pathogenic assertion exists. |
cspec
clinvar
|
| BA1 | Not met | Not met: gnomAD Popmax AF is 1.127e-05 at most, below the APC VCEP BA1 threshold of 0.001. |
cspec
gnomad_v2
gnomad_v4
|
| BS1 | Met | Met: gnomAD v2.1 Popmax AF 1.127e-05 exceeds the APC VCEP BS1 threshold of 0.00001, despite a lower v4.1 estimate. |
cspec
gnomad_v2
gnomad_v4
|
| BS2 | Not assessed | Not assessed: gnomAD reports 0 homozygotes, but no VCEP-defined healthy-individual age and phenotype points are available. |
cspec
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no validated assay shows wild-type-comparable beta-catenin transcription activity or benign RNA behavior for APC p.Arg1069Gly. |
cspec
PMID:34545850
|
| BS4 | Not assessed | Not assessed: no affected non-carrier or phenotype-point evidence is documented to meet the APC VCEP BS4 thresholds. |
cspec
PMID:34545850
|
| BP1 | Met | Met, supporting: p.Arg1069Gly is at codon 1069, outside the APC BP1 exception spanning codons 1021-1035. |
cspec
|
| BP2 | Not assessed | Not assessed: two reported patients lack documented trans phase or a second pathogenic APC variant, while the VCEP requires trans observation or three unknown-phase occurrences. |
cspec
PMID:34545850
|
| BP3 | N/A | Not applicable: p.(Arg1069Gly) is a missense substitution, not an in-frame indel in a repetitive region required for BP3. |
cspec
vcep_apc_specifications_supplementary_material_v2
|
| BP4 | N/A | Not applicable: the APC VCEP excludes BP4 for missense variants, so no predictor score is evaluated for this criterion. |
cspec
|
| BP5 | Not met | Not met: no qualifying alternate-gene Pathogenic or Likely pathogenic finding is documented for a colorectal polyposis phenotype. |
cspec
PMID:34545850
|
| BP6 | N/A | Not applicable: the APC VCEP prohibits BP6, and no exact-variant ClinVar expert-panel Benign or Likely benign assertion exists. |
cspec
clinvar
|
| BP7 | N/A | Not applicable: BP7 is restricted to synonymous or qualifying intronic variants, whereas this variant is missense. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.